Across TCGA pan-cancer cohorts, SATB1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SATB1 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SATB1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SATB1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, BRCA, and PRAD are the cancer types where SATB1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	24	view →
BRCA	OS	Median	III,IV	0.027	0.907	<.001	17	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
KIRP	OS	Median	All	0.680	0.903	.046	3	view →
SKCM	OS	Median	II,III,IV	0.964	0.829	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SATB1 tumor-vs-normal RNA expression · all SATB1 data types